key articles
Sex hormone-binding globulin to predict extraprostatic tumor extension of prostate cancer patients
Friday, 16 May 2008 - Lee et al. (Lee et al., 2008) investigated the relationships of serum sex hormone-binding globulin (SHBG) level with known prognostic factors for prostate cancer in men who received radical retropubic...
Predicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer
Friday, 16 May 2008 - Outcome data from a prospective study of active surveillance of localised prostate cancer were analysed by van As et al. (2008) to identify factors, present at the time of diagnosis, that predict...
Authors: van As
Prostate-specific antigen velocity and prostate cancer distant metastases
Thursday, 15 May 2008 - In men with prostate cancer, pretreatment prostate-specific antigen velocity (PSAV) is a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of...
Authors: Palma et al.
The prognostic role of the pathological T2 subclassification for prostate cancer
Wednesday, 14 May 2008 - Van Oort et al. (2008) evaluated the prognostic role of the 2002 Tumour-Nodes-Metastasis (TNM) pT2 subclassification for biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate...
Authors: van Oort
Progression after radical prostatectomy for men in their thirties compared to older men
Wednesday, 14 May 2008 - Loeb et al. (2008) assessed the biochemical outcome after radical prostatectomy (RP) specifically for men aged 30-39 years, as previous studies suggest that prostate cancer in young men might be more...
Authors: Loeb et al.
Prostate-specific antigen velocity thresholds in clinical practice
Tuesday, 13 May 2008 - Connolly et al. (2008) investigated the ability of prostate-specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying...
Authors: Connolly et al.
Better androgen deprivation therapy for prostate cancer
Tuesday, 13 May 2008 - Anderson et al. (2008) addressed future needs of better androgen deprivation therapy for prostate cancer. Gonadotrophin-releasing hormone (GnRH) agonists are currently the mainstay in the management of...
Authors: Anderson et al.
Prostate cancer vaccines: current status and future potential
Monday, 12 May 2008 - Doehn et al. (2008) reviewed the state of the art of prostate cancer vaccines. Standard systemic treatment of prostate cancer today is comprised of antihormonal and cytostatic agents. Vaccine therapy of...
Authors: Doehn et al.
Prostate specific antigen-containing macrophages for detecting prostate cancer
Monday, 12 May 2008 - A major problem of serum prostate-specific antigen (PSA) for predicting prostate cancer risk is diagnostic uncertainty. To detect circulating macrophages with phagocytized fragments (for example PSA) of...
Authors: Leers et al.
Prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis
Sunday, 11 May 2008 -In a review, Hochreiter (2008) discussed prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Elevated levels of prostate-specific antigen (PSA) in men may result...
Author: Hochreiter
